<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765570</url>
  </required_header>
  <id_info>
    <org_study_id>GRID</org_study_id>
    <nct_id>NCT00765570</nct_id>
  </id_info>
  <brief_title>Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy</brief_title>
  <official_title>Treatment of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy A Phase II Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Summa Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Summa Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Expand clinical literature on the use of Grid radiation with conventional external beam
      therapy. Vast majority of therapy is for palliative care to provide relief from pain, but has
      also shown a reduction in the size of tumor mass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate response to radiation therapy by a large bulky tumor is influenced
      by adding a single dose of 15 Gy grid radiotherapy. To accomplish this, patients with large
      bulky tumors in the lung, abdomen or pelvis will be randomized to receive either standard
      palliative radiation or palliative radiation plus a single fraction of grid radiation. Tumor
      response, pain relief and duration of response, and pain control will be monitored. Toxicity
      of treatment will also be followed. The hypothesis of this study is that grid radiation will
      produce a significant improvement in tumor response and pain control that produces no further
      increase in acute or late toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual too slow - would not enroll enough subjects to determine outcome
  </why_stopped>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protocol Treatment Related Morbidity</measure>
    <time_frame>during duration of treatment of 3 weeks. Follow up exams every 6 months for the next two years and then yearly for the rest of your life.</time_frame>
    <description>Number of grade 3 or higher complications during the assesment period. This does not include any complication felt to be due solely to malignancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response of Bulky Tumors of the Head and Neck Area, Lung, Abdomen or Pelvis to Standard Fractionated Radiation Therapy Plus Grid Therapy Compared to Standard Fractionated Radiation Therapy Alone.</measure>
    <time_frame>during duration of treatment of 3 weeks. Follow up exams every 6 months for the next two years and then yearly for the rest of your life.</time_frame>
    <description>Complete response (CR) = 100% tumor disappearance Partial response (PR) = &gt; 50% reduction in size Stable disease (SD) = &lt; 50% reduction or no change +/- 10% increase in tumor size Progressive disease (PD) = &gt; 10% increase in size of tumor Unknown Status (UK)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Advanced Bulky Malignancies</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Group 2-15 treatments with standard radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Spatially Fractioned Radiation Therapy</intervention_name>
    <description>evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <other_name>GRID Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Treatment Group 1</intervention_name>
    <description>one treatment of Grid therapy followed by 15 treatments with standard radiation</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard radiation</intervention_name>
    <description>15 Standard radiation treatments</description>
    <arm_group_label>Treatment Group-2</arm_group_label>
    <other_name>Treatment Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard radiation</intervention_name>
    <description>standard radiation treatment</description>
    <arm_group_label>Treatment Group-2</arm_group_label>
    <other_name>Treatment Group 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologic or cytologic diagnosis of primary or metastatic epithelial
             cancer or sarcoma located in the head and neck area, lung, abdomen or pelvis.

          -  Tumors must have an overall dimension greater than 24 cm2 (bidimensional) with one
             dimensions &gt;6 cm, by x-ray, CT/MRI scan or clinical exam.

          -  Age &gt;18

          -  Karnofsky &gt; 70 with life expectancy &gt;3 months.

          -  Patients may not begin new hormone therapy within 2 weeks of initiation of protocol
             treatment.

          -  No planned initiation of hormone therapy within 2 weeks of protocol therapy

          -  Adequate bone marrow function: Hb &gt; 9, white blood cell count (WBC) &gt; 2,000. Hepatic
             function &lt; 3x upper limit of laboratory normal values.

          -  Laboratory studies will be obtained within 2 weeks prior to randomization.

          -  Patients with metastatic sites of disease including brain are eligible provided that
             life expectancy is &gt; 3 months.

        Exclusion Criteria:

          -  Hematologic-related tumors.

          -  Tumors overlying critical central nervous system structures including spinal cord, eye
             or brainstem or require treatment portals over these vital structures.

          -  Central nervous system tumors

          -  Evidence of other primary malignancy except for carcinoma in situ of cervix or skin
             cancer excluding melanoma unless disease free for 2 years prior to randomization

          -  Patients with spinal cord compression.

          -  Prior radiation to treatment field.

          -  Concomitant chemotherapy or chemotherapy within past 2 weeks. Planned initiation of
             chemotherapy within 2 weeks of completing protocol treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Seider, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Summa Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <results_first_submitted>February 16, 2015</results_first_submitted>
  <results_first_submitted_qc>February 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2015</results_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>large tumors in the head &amp; neck, lung, abdomen or pelvis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled from the physicians offices at Summa Health System.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group 1</title>
          <description>Treatment Group 1: one treatment of Grid therapy followed by 15 treatments with standard radiation</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group-2</title>
          <description>Treatment Group 2:15 treatments with standard radiation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group 1</title>
          <description>Treatment Group 1: one treatment of Grid therapy followed by 15 treatments with standard radiation</description>
        </group>
        <group group_id="B2">
          <title>Treatment Group-2</title>
          <description>Treatment Group 2: 15 treatments with standard radiation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="12"/>
                    <measurement group_id="B2" value="69" spread="9"/>
                    <measurement group_id="B3" value="72" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Protocol Treatment Related Morbidity</title>
        <description>Number of grade 3 or higher complications during the assesment period. This does not include any complication felt to be due solely to malignancy</description>
        <time_frame>during duration of treatment of 3 weeks. Follow up exams every 6 months for the next two years and then yearly for the rest of your life.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>Treatment Group 1: one treatment of Grid therapy followed by 15 treatments with standard radiation</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group-2</title>
            <description>Treatment Group 2: 15 treatments with standard radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Protocol Treatment Related Morbidity</title>
          <description>Number of grade 3 or higher complications during the assesment period. This does not include any complication felt to be due solely to malignancy</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response of Bulky Tumors of the Head and Neck Area, Lung, Abdomen or Pelvis to Standard Fractionated Radiation Therapy Plus Grid Therapy Compared to Standard Fractionated Radiation Therapy Alone.</title>
        <description>Complete response (CR) = 100% tumor disappearance Partial response (PR) = &gt; 50% reduction in size Stable disease (SD) = &lt; 50% reduction or no change +/- 10% increase in tumor size Progressive disease (PD) = &gt; 10% increase in size of tumor Unknown Status (UK)</description>
        <time_frame>during duration of treatment of 3 weeks. Follow up exams every 6 months for the next two years and then yearly for the rest of your life.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group 1</title>
            <description>Treatment Group 1: one treatment of Grid therapy followed by 15 treatments with standard radiation</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group-2</title>
            <description>Treatment Group 2: 15 treatments with standard radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response of Bulky Tumors of the Head and Neck Area, Lung, Abdomen or Pelvis to Standard Fractionated Radiation Therapy Plus Grid Therapy Compared to Standard Fractionated Radiation Therapy Alone.</title>
          <description>Complete response (CR) = 100% tumor disappearance Partial response (PR) = &gt; 50% reduction in size Stable disease (SD) = &lt; 50% reduction or no change +/- 10% increase in tumor size Progressive disease (PD) = &gt; 10% increase in size of tumor Unknown Status (UK)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown (UK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were to be assessed at 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, 9 months and 1 year after treatment was completed. Follow-up after 1 year was to be at 6 month intervals until 2 years, then annually.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group 1</title>
          <description>Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation</description>
        </group>
        <group group_id="E2">
          <title>Treatment Group-2</title>
          <description>Treatment Group 2-15 treatments with standard radiation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI or GU Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung Toxicity</sub_title>
                <description>cough, dyspnea</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tracy Mondello, MS</name_or_title>
      <organization>Summa Health System</organization>
      <phone>330-375-6131</phone>
      <email>mondellot@summahealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

